/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

XERIS BIOPHARMA HOLDINGS INC Share Price Today: Live Updates & Key Insights

XERIS BIOPHARMA HOLDINGS INC share price today is $5.48, up -4.36%. The stock opened at $5.6451 against the previous close of $5.73, with an intraday high of $5.6451 and low of $5.385.

XERIS BIOPHARMA HOLDINGS INC Share Price Chart

style
pb-0

XERIS BIOPHARMA HOLDINGS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

XERIS BIOPHARMA HOLDINGS INC Share Price Performance

$5.48 -0.0436(-4.36%) XERS at 13 Mar 2026 03:56 PM Biotechnology
Lowest Today 5.385
Highest Today 5.6451
Today’s Open 5.6451
Prev. Close 5.73
52 Week High 10.08
52 Week Low 3.81
Day’s Range: Low 5.385 High 5.6451
52-Week Range: Low 3.81 High 10.08
1 day return -
1 Week return -5.34
1 month return -19.56
3 month return -22.23
6 month return -25.3
1 year return +20.13
3 year return +353.71
5 year return +20.92
10 year return -

XERIS BIOPHARMA HOLDINGS INC Institutional Holdings

BlackRock Inc 6.92

Vanguard Group Inc 6.49

D. E. Shaw & Co LP 4.39

Vanguard Total Stock Mkt Idx Inv 2.87

Geode Capital Management, LLC 2.40

iShares Russell 2000 ETF 2.17

State Street Corp 2.17

Qube Research & Technologies 1.90

Morgan Stanley - Brokerage Accounts 1.87

Driehaus Capital Management LLC 1.73

Nuveen, LLC 1.63

Wellington Management Company LLP 1.33

Rosalind Advisors, Inc. 1.22

JPMorgan Chase & Co 1.05

The Goldman Sachs Group Inc 1.04

Vanguard Institutional Extnd Mkt Idx Tr 1.04

UBS Group AG 1.03

Two Sigma Investments LLC 1.00

Parkman Healthcare Partners LLC 0.98

Bank of America Corp 0.92

Deutsche Bank AG 0.91

Fidelity Small Cap Index 0.87

Prudential Financial Inc 0.83

Charles Schwab Investment Management Inc 0.81

iShares Russell 2000 Growth ETF 0.74

Nuveen Quant Small Cap Equity R6 0.71

Heptagon Driehaus US Micro Cap Eq C$ Acc 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.51

State Street® SPDR® S&P® PhrmctlsETF 0.51

Fidelity Extended Market Index 0.50

SSgA Russell Small Cap Completeness Idx 0.49

Schwab US Small-Cap ETF™ 0.46

Vanguard Russell 2000 ETF 0.42

CREF Total Global Stock Account R3 0.37

Vanguard Explorer Inv 0.35

Kennedy Micro Cap 0.34

State St Russell Sm Cap® Indx SL Cl I 0.29

Vanguard Health Care ETF 0.28

Nuveen Quant Small/Mid Cap Eq R6 0.27

Xtrackers S&P 500 Swap ETF 1C 0.27

XERIS BIOPHARMA HOLDINGS INC Market Status

Strong Buy: 4

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

XERIS BIOPHARMA HOLDINGS INC Fundamentals

Market Cap 988.03 M

PB Ratio 72.177

PE Ratio 0.0

Enterprise Value 1135.09 M

Total Assets 383.53 M

Volume 2142551

XERIS BIOPHARMA HOLDINGS INC Company Financials

Annual Revenue FY23:152668000 152.7M, FY22:110248000 110.2M, FY21:49590000 49.6M, FY20:20155000 20.2M, FY19:2722000 2.7M

Annual Profit FY23:125302000 125.3M, FY22:87614000 87.6M, FY21:36272000 36.3M, FY20:10827000 10.8M, FY19:1119000 1.1M

Annual Net worth FY23:-61795000 -61.8M, FY22:-94660000 -94.7M, FY21:-122725000 -122.7M, FY20:-91140000 -91.1M, FY19:-125580000 -125.6M

Quarterly Revenue Q3/2025:74380000 74.4M, Q2/2025:71539000 71.5M, Q1/2025:60119000 60.1M, Q3/2024:54268000 54.3M, Q2/2024:48065000 48.1M

Quarterly Profit Q3/2025:63384000 63.4M, Q2/2025:56930000 56.9M, Q1/2025:51391000 51.4M, Q3/2024:40675000 40.7M, Q2/2024:37565000 37.6M

Quarterly Net worth Q3/2025:621000 0.6M, Q2/2025:-1928000 -1.9M, Q1/2025:-9220000 -9.2M, Q3/2024:-15738000 -15.7M, Q2/2024:-15005000 -15.0M

About XERIS BIOPHARMA HOLDINGS INC & investment objective

Company Information Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Organisation Biotechnology

Employees 435

Industry Biotechnology

CEO Mr. John P. Shannon

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow